Sojournix

What Sojournix does

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, focused on developing innovative therapeutics for women's health and endocrine disorders. The company operates with a small, specialized team of 11-50 employees, consistent with an R&D-driven organization at the preclinical-to-early-clinical stage.

Sojournix has financed its operations primarily through equity capital, completing three disclosed funding rounds that together total approximately $70 million. The most significant was a $44.0 million Series 3 closed in January 2019 and led by RA Capital Management, with participation from Boxer Capital, Frazier Healthcare Partners, Janus Henderson Investors, and Venrock Healthcare Capital Partners. Earlier rounds of $7.0 million (May 2017) and $19.0 million (December 2017) supported the company's earlier development work. The investor base is composed of dedicated healthcare-focused funds, which is consistent with a clinical pipeline rather than a commercial-stage operation.

The company is led by Daniel Grau as President, Chief Executive Officer, and Director, with Peter Lanciano serving as Chairman of the Board and Chairman of the Audit Committee. No commercial products, partnerships, licensing agreements, or revenue-generating activities were disclosed in the source material, and the company's therapeutic pipeline and specific drug candidates were not detailed. Note: scraped content from the sojournixpharma.com domain references unrelated third-party entities (a gambling platform and a footwear brand) and is not consistent with Sojournix's stated biotech focus, suggesting domain repurposing rather than first-party Sojournix content.

Name

Sojournix

Legal name

PEDANGWIN

Website

https://sojournixpharma.com

Company type

Private

Founded year

2016

Headcount range

11–50 employees

Short description

Sojournix is a private, clinical-stage biotechnology company founded in 2016 and headquartered in Arlington, Massachusetts, developing therapeutics for women's health and endocrine disorders, backed by approximately $70 million in venture funding from healthcare-focused investors.

Ownership category

akta.pro rank

Product category

Women's health biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Women's health therapeutics
• Endocrine disorder treatments
• Clinical-stage biopharmaceuticals
• Women's health drug development
• Endocrine medicine pipeline

Headquarters

HQ city

Arlington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Core offering

Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. The company is engaged in therapeutic research and clinical-stage drug development targeting these underserved disease areas, with operations supported by venture capital funding.

Product overview

VIVAIA is a sustainable footwear brand offering a comprehensive collection of comfortable shoes made from recycled plastic bottles. The product portfolio includes core footwear categories (Flats, Sneakers, Loafers, Boots, Heels, Sandals, and Kids shoes) as well as Bags & Accessories. The brand is organized around several named collections including Slip On Revolution, Sport Sandals, Lightweight Wonderland, and Walker Pro Collection, supported by two loyalty programs: V-PLUS (membership with discount benefits) and V-POINTS (rewards points system). The company emphasizes sustainability messaging, noting products are made from recycled materials including 6 plastic bottles per pair.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• TherapeuticsMD: TherapeuticsMD was a women's-health-focused pharmaceutical company developing and commercializing products in menopause, hormone therapy, and reproductive health — directly comparable to Sojournix's stated women's health and endocrine focus. Both companies target the same prescriber base and similar patient populations in menopause and women's endocrine care.
• Mithra Pharmaceuticals: Mithra is a Belgian specialty pharma focused on women's health, with development and commercialization programs in contraception, menopause (Estelle), and hormone therapy. It is a direct comparable in the women's-health specialty-pharma category Sojournix operates in.
• Dare Bioscience: Dare Bioscience is a clinical-stage biopharmaceutical company focused exclusively on women's health, with a portfolio spanning contraception, menopause, and reproductive health. It is a direct peer in business model, stage, and therapeutic focus to Sojournix.

Broad incumbents

• Organon & Co. Organon is a global women's health pharmaceutical company spun out of Merck, with a broad portfolio across contraception, fertility, menopause, and biosimilars. It is a broad incumbent serving the same end markets and patient populations Sojournix targets, but at a much larger scale and across many therapeutic areas.
• Astellas Pharma (Veozah / fezolinetant): Astellas developed and commercializes Veozah (fezolinetant), an FDA-approved neurokinin 3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms — the most directly relevant large-pharma incumbent in Sojournix's likely target indication.
• Bayer (Women's Health / menopause pipeline): Bayer operates a global women's health franchise spanning contraception, menopause, and gynecological therapies. As a broad incumbent with deep commercial reach, it is a credible large-pharma comparator and a potential acquirer of specialty women's health assets.
• AbbVie (women's health and endocrinology): AbbVie has a meaningful endocrinology and women's health franchise (including elagolix via partnership) and is a large-pharma incumbent whose pipeline priorities overlap with Sojournix's therapeutic areas, particularly in reproductive and endocrine disorders.
• Hologic (women's health diagnostics and therapeutics): Hologic is a women's-health-focused company spanning diagnostics, surgical, and increasingly therapeutics. While historically diagnostics-led, its strategic interest in women's health therapeutics makes it a comparable broad incumbent and a potential strategic acquirer.

Emerging players

• Estetra SRL (a Mithra subsidiary): Estetra develops next-generation oral contraceptives and women's health products within the Mithra group, with focus on estrogen-based therapies. It is an emerging peer operating in overlapping women's endocrine indications relevant to Sojournix.
• NeuroBo Therapeutics (DA-1726 / DA-1241): NeuroBo Therapeutics is a clinical-stage biotech developing therapeutics that act on metabolic and endocrine pathways. It is an emerging peer in modality and stage to Sojournix, with overlap in endocrine-focused clinical development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks1 record

Key highlights5 records

Customer concentration

• Xfacebook.com/groups/1119180448492469
• YouTubevivaia.com/blogs
• LinkedInlinkedin.com/company/sojournix

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sojournix